“SPL7013 products which the company has always claimed was a sideshow is the only thing that has the potential to generate any sort of half meaningful income and they have just slipped it into the too hard basket whilst making a less than quarter baked attempt at marketing the products overseas.”
not according to Chairman of Board - the newer direction ie doing no more about Viraleze SPL7013 registration in Australian ARTG or VivaGel in US will not generate nearly the income potential of DEP products and there was a reluctance in challenging the duplicity of the Health Dept that awarded grant 2020 and best awardee results 2022 whilst the section within the Dept -TGA guillotined Viraleze at 11 months of a 12 month grant timeline. Surely complaining to the minister who is over the entire department DOHAC is the least the chair and board should consider. If the TGA were told to approve the existing archived application it would be simple and cheap way to pharmacy shelves.
Ann: Results of 2024 Reconvened Annual General Meeting, page-6
Add to My Watchlist
What is My Watchlist?
